Jasper Therapeuti…
USUSDJasper Therapeutics, Inc. (US:JSPR) — Biotechnology: Biological Products (No Diagnostic Substances). Número de bolsas en las que cotizan las acciones de la empresa: 1. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la empresa
- Sitio web
- jaspertx.com
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sede central
- REDWOOD CITY, United States
- Acciones en circulación
- 33.27 M a 2026-08-10
- Capitalización bursátil
- 20.83 M USD
- Insiders
- 2.87%
- Inversores institucionales
- 39.43%
- Industria (SIC)
- Biological Products, (No Diagnostic Substances)
Descripción
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.
Bolsas y tickers
| Bolsa | Ticker | Moneda | Precio | Tipo |
|---|---|---|---|---|
| US USA Stocks | JSPR | USD | 0.56 -1.70% | acciones ordinarias |
Dividendos
No se han encontrado pagos de dividendos (comprobado el 09.10.2026). Es probable que la empresa no reparta dividendos.
Noticias de esta semana
Aún no hay noticias del sitio web de la empresa.
Principales accionistas
| Titular | Participación | Acciones | Fecha del informe |
|---|---|---|---|
| Velan Capital Investment… | 16.04% | 5.34 M | 2026-06-30 |
| Acorn Capital Advisors,… | 8.64% | 2.88 M | 2026-06-30 |
| Kingdon Capital Manageme… | 8.13% | 2.7 M | 2026-06-30 |
| Vanguard Capital Managem… | 7.04% | 2.34 M | 2026-06-30 |
| Rock Springs Capital Man… | 6.62% | 2.2 M | 2026-06-30 |
| Carlyle Group Inc. | 6.41% | 2.13 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 5.01% | 1.67 M | 2026-06-30 |
| GSA Capital Partners LLP | 3.21% | 1.07 M | 2026-06-30 |
| Millennium Management Ll… | 2.93% | 973 866 | 2026-06-30 |
| Lion Point Capital, LP | 2.79% | 930 000 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.88% | 624 064 | 2026-06-30 |
| Geode Capital Management… | 1.59% | 527 616 | 2026-06-30 |
| SHIZURU JUDITH ANNE M.D.… | ≈0.47% | 156 901 | 2025-09-22 |
| Fidelity Concord Street… | 0.38% | 127 525 | 2026-07-31 |
| MARTELL RONALD A (Chief… | ≈0.22% | 74 118 | 2025-09-22 |
| VANGUARD VALLEY FORGE FU… | 0.16% | 53 196 | 2026-06-30 |
| Fidelity Concord Street… | 0.15% | 49 896 | 2026-07-31 |
| Fidelity Concord Street… | 0.1% | 34 109 | 2026-07-31 |
| MAHAL JEETINDER SINGH (C… | ≈0.08% | 25 009 | 2024-12-12 |
| LUCAS SVETLANA (Director… | ≈0.06% | 20 000 | 2025-09-22 |
| ADVISORS' INNER CIRCLE I… | 0% | 292 | 2026-04-30 |
| WIGGANS THOMAS G (Direct… | — | — | 2025-09-22 |
